# Acadia Healthcare Company, Inc.: Form 10-Q for the period ended Sep 30, 2022

- Company: [Acadia Healthcare Company, Inc.](/companies/achc.md) (CIK 1520697)
- Form: 10-Q
- Filed: 2022-11-02
- Accepted by EDGAR: Nov 2, 2022, 13:48 ET
- Period: 2022-09-30
- Accession: 0001564590-22-036269
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1520697/000156459022036269/achc-10q_20220930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1520697/000156459022036269/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-07-01 to 2022-09-30 | $666.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2022-01-01 to 2022-09-30 | $1.94bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Income tax | 3 months, 2022-07-01 to 2022-09-30 | $24.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2022-01-01 to 2022-09-30 | $69.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-07-01 to 2022-09-30 | $71.1m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2022-01-01 to 2022-09-30 | $212.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-07-01 to 2022-09-30 | $0.78 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2022-01-01 to 2022-09-30 | $2.31 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-07-01 to 2022-09-30 | $0.79 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2022-01-01 to 2022-09-30 | $2.37 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-07-01 to 2022-09-30 | 91,723,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2022-01-01 to 2022-09-30 | 91,668,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2022-01-01 to 2022-09-30 | $267.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2022-01-01 to 2022-09-30 | $208.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2022-09-30 | $93.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-09-30 | $521.7m | us-gaap:AssetsCurrent |
| Total assets | at 2022-09-30 | $4.94bn | us-gaap:Assets |
| Current liabilities | at 2022-09-30 | $401.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-09-30 | $2.11bn | us-gaap:Liabilities |
| Long-term debt | at 2022-09-30 | $1.38bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2022-09-30 | $21.3m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2022-09-30 | $2.74bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 54,841 characters.

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements that address future results or occurrences. In some cases you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “would,” “should,” “could” or the negative thereof. Generally, the words “anticipate,” “believe,” “continue,” “expect,” “intend,” “estimate,” “project,” “plan” and similar expressions identify forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are forward-looking statements.

We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks, uncertainties and other factors, many of which are outside of our control, which could cause our actual results, performance or achievements to differ materially from any results, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors include, but are not limited to:

- the impact of the COVID-19 pandemic on our inpatient and outpatient volumes, or disruptions caused by other pandemics, epidemics or outbreaks of infectious diseases;
- the impact of vaccine and other pandemic-related mandates imposed by local, state and federal authorities on our business;
- costs of providing care to our patients, including increased staffing, equipment and supply expenses resulting from the COVID-19 pandemic;
- our ability to integrate Christopher H. Hunter, our new chief executive officer;
- the impact of competition for staffing on our labor costs and profitability;
- the impact of increases to our labor costs;
- the impact of general economic and employment conditions, including increased construction and other costs due to inflation, on our business and future results of operations;
- the occurrence of patient incidents, which could result in negative media coverage, adversely affect the price of our securities and result in incremental regulatory burdens and governmental investigations;
- our significant indebtedness, our ability to meet our debt obligations, and our ability to incur substantially more debt;
- our ability to implement our business strategies, especially in light of the COVID-19 pandemic;
- the impact of payments received from the government and third-party payors on our revenue and results of operations;
- difficulties in successfully integrating the operations of acquired facilities or realizing the potential benefits and synergies of our acquisitions and joint ventures;
- our ability to recruit and retain quality psychiatrists and other physicians, nurses, counselors and other medical support personnel;
- our future cash flow and earnings;
- our restrictive covenants, which may restrict our business and financing activities;
- the impact of adverse weather conditions, including the effects of hurricanes and wildfires;
- compliance with laws and government regulations;
- the impact of claims brought against us or our facilities including claims for damages for personal injuries, medical malpractice, overpayments, breach of contract, securities law violations, tort and employee related claims;
- the impact of governmental investigations, regulatory actions and whistleblower lawsuits;
- any failure to comply with the terms of our corporate integrity agreement with the OIG;
- the impact of healthcare reform in the U.S.;
- the risk of a cyber-security incident and any resulting adverse impact on our operations or violation of laws and regulations regarding information privacy;
- the impact of our highly competitive industry on patient volumes;
- our dependence on key management personnel, key executives and local facility management personnel;
- our acquisition, joint venture and wholly-owned de novo strategies, which expose us to a variety of operational and financial risks, as well as legal and regulatory risks;
- the impact of state efforts to regulate the construction or expansion of healthcare facilities on our ability to operate and expand our operations;
- our potential inability to extend leases at expiration;
- the impact of controls designed to reduce inpatient services on our revenue;
- the impact of different interpretations of accounting principles on our results of operations or financial condition;
- the impact of environmental, health and safety laws and regulations, especially in locations where we have concentrated operations;
- the impact of laws and regulations relating to privacy and security of patient health information and standards for electronic transactions;
- our ability to cultivate and maintain relationships with referral sources;
- the impact of a change in the mix of our earnings, adverse changes in our effective tax rate and adverse developments in tax laws generally;
- changes in interpretations, assumptions and expectations regarding recent tax legislation, including provisions of the CARES Act and additional guidance that may be issued by federal and state taxing authorities;
- failure to maintain effective internal control over financial reporting;
- the impact of fluctuations in our operating results, quarter to quarter earnings and other factors on the price of our securities;
- the impact of the trend for insurance companies and managed care organizations to enter into sole source contracts on our ability to obtain patients;
- the impact of value-based purchasing programs on our revenue; and
- those risks and uncertainties described from time to time in our filings with the SEC.

Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. These risks and uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. These forward-looking statements are made only as of the date of this Quarterly Report on Form 10-Q. We do not undertake and specifically decline any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments.

### Overview

Our business strategy is to acquire and develop behavioral healthcare facilities and improve our operating results within our facilities and our other behavioral healthcare operations. We strive to improve the operating results of our facilities by providing high-quality services, expanding referral networks and marketing initiatives while meeting the increased demand for behavioral healthcare services through expansion of our current locations as well as developing new services within existing locations. At September 30, 2022, we operated 242 behavioral healthcare facilities with approximately 10,800 beds in 39 states and Puerto Rico. During the nine months ended September 30, 2022, we added 360 beds in the U.S., consisting of 210 added to existing facilities and 150 added through the opening of one wholly-owned facility and one joint venture facility, and opened four CTCs. For the year ending December 31, 2022, we expect to (i) add approximately 300 beds to existing facilities, (ii) add 270 beds through the opening of one wholly-owned facility and two joint venture facilities, and (iii) open at least six CTCs.

We are the leading publicly traded pure-play provider of behavioral healthcare services in the United States. Management believes that we are positioned as a leading platform in a highly fragmented industry under the direction of an experienced management team that has significant industry expertise. Management expects to take advantage of several strategies that are more accessible as a result of our increased size and geographic scale, including continuing a national marketing strategy to attract new patients and referral sources, increasing our volume of out-of-state referrals, providing a broader range of services to new and existing patients and clients and selectively pursuing opportunities to expand our facility and bed count in the U.S. through acquisitions, wholly-owned de novo facilities, joint ventures and bed additions in existing facilities.

On January 19, 2021, we completed the U.K. Sale pursuant to a Share Purchase Agreement in which we sold all of the securities of AHC-WW Jersey Limited, a private limited liability company incorporated in Jersey and a subsidiary of the Company, which constituted the entirety of our U.K. business operations. The U.K. Sale resulted in approximately $1,525 million of gross proceeds before deducting the settlement of existing foreign currency hedging liabilities of $85 million based on the current GBP to USD exchange rate, cash retained by the buyer and transaction costs. We used the net proceeds of approximately $1,425 million (excluding cash retained by the buyer) along with cash from the balance sheet to reduce debt by $1,640 million during the first quarter of 2021. As a result of the U.K. Sale, we reported, for all periods presented, results of operations and cash flows of the U.K. operations as discontinued operations in the accompanying financial statements.

### COVID-19

During March 2020, the global pandemic of COVID-19 began to affect our facilities, employees, patients, communities, business operations and financial performance, as well as the broader U.S. and U.K. economies and financial markets. At many of our facilities, employees and/or patients have tested positive for COVID-19. We are committed to protecting the health of our communities and have been responding to the evolving COVID-19 situation while taking steps to provide quality care and protect the health and safety of our patients and employees. Over the last two years, all of our facilities have closely followed infectious disease protocols, as well as recommendations by the CDC and local health officials.

We have taken numerous steps to help minimize the impact of the virus on our patients and employees. For example, we:

- established an internal COVID-19 taskforce;
- instituted social distancing practices and protective measures throughout our facilities, which included restricting or suspending visitor access, screening patients and staff who enter our facilities based on criteria established by the CDC and local health officials, and testing and isolating patients when warranted;
- implemented plans to vaccinate all eligible employees at our facilities that participate in CMS reimbursement programs;
- secured contracts with additional distributors for supplies;
- expanded telehealth capabilities;
- implemented emergency planning in directly impacted markets; and
- limited all non-essential business travel and suspended in-person trainings and conferences.

We have developed additional supply chain management processes, which includes extensive tracking and delivery of key personal protective equipment (“PPE”) and supplies and sharing resources across all facilities. We could experience supply chain disruptions and significant price increases in equipment, pharmaceuticals and medical supplies, particularly PPE. Pandemic-related staffing difficulties and equipment, pharmaceutical and medical supplies shortages may impact our ability to treat patients at our facilities. Such shortages could lead to us paying higher prices for supplies, equipment and labor and an increase in overtime hours paid to our employees.

### CARES Act and Other Regulatory Developments

On March 27, 2020, the CARES Act was signed into law. The CARES Act is intended to provide over $2 trillion in stimulus benefits for the U.S. economy. Among other things, the CARES Act includes additional support for small businesses, expands unemployment benefits, makes forgivable loans available to small businesses, provides for certain federal income tax changes, and provides $500 billion for loans, loan guarantees, and other investments for or in U.S. businesses.

In addition, the CARES Act contains a number of provisions that are intended to assist healthcare providers as they combat the effects of the COVID-19 pandemic. Those provisions include, among others:

- an appropriation to the PHSSE Fund to reimburse, through grants or other mechanisms, eligible healthcare providers and other approved entities for COVID-19-related expenses or lost revenue;
- the expansion of CMS’ Accelerated and Advance Payment Program;
- the temporary suspension of Medicare sequestration; and
- waivers or temporary suspension of certain regulatory requirements.

The U.S. government initially announced it would offer $100 billion of relief to eligible healthcare providers through the PHSSE Fund. On April 24, 2020, then President Trump signed into law the PPP Act. Among other things, the PPP Act allocated $75 billion to eligible healthcare providers to help offset COVID-19 related losses and expenses. The $75 billion allocated under the PPP Act is in addition to the $100 billion allocated to healthcare providers for the same purposes in the CARES Act and has been disbursed to providers under terms and conditions similar to the CARES Act funds. In 2020, we received approximately $34.9 million of the funds distributed from the PHSSE Fund. During the fourth quarter of 2020, the Company recorded approximately $32.8 million of income from provider relief fund related to PHSSE funds received in 2020.

In 2021, we received $24.2 million of additional funds from the PHSSE Fund. During the fourth quarter of 2021, we recorded $17.9 million of income from provider relief fund related to the PHSSE funds received. During the nine months ended September 30, 2022, we received $7.7 million of additional funds from the PHSSE Fund and $14.2 million from the ARP Rural Payments for Hospitals. During the nine months ended September 30, 2022, we recorded $16.2 million of income from provider relief fund related to PHSSE funds received. We continue to evaluate our compliance with the terms and conditions to, and the financial impact of, these additional funds received.

Using existing authority and certain expanded authority under the CARES Act, the U.S. Department of Health & Human Services (“HHS”) expanded CMS’ Accelerated and Advance Payment Program to a broader group of Medicare Part A and Part B providers for the duration of the COVID-19 pandemic. Under the program, certain of our facilities were eligible to request up to 100% of their Medicare payment amount for a three-month period. Under the original terms of the program, the repayment of these accelerated/advanced payments would have begun 120 days after the date of the issuance of the payment and the amounts advanced to our facilities would have been recouped from new Medicare claims as a 100% offset. Our facilities would have had 210 days from the date the accelerated or advance payment was made to repay the amounts that they owe.

On October 1, 2020, Congress amended the terms of the Accelerated and Advance Payment Program to extend the term of the loan and adjust the repayment process. Under the new terms of the program, all providers will have 29 months from the date of their first program payment to repay the full amount of the accelerated or advance payments they have received. The revised terms extend the period before repayment begins from 210 days to one year from the date that payment under the program was received. Once the repayment period begins, the offset is limited to 25% of new claims during the first 11 months of repayment and 50% of new claims during the final 6 months. The revised program terms also lower the interest rate on outstanding amounts due at the end of the repayment period from 10% to 4%. We applied for and received approximately $45.2 million in 2020 from this program. Of the $45.2 million of advance payments received in 2020, we repaid approximately $25.1 million of advance payments during 2021 and made additional repayments of approximately $18.9 million during the nine months ended September 30, 2022. We will pay off the remaining balance of $1.2 million in the fourth quarter of 2022.

Under the CARES Act, we also received a 2% increase in our facilities’ Medicare reimbursement rate as a result of the temporary suspension of Medicare sequestration from May 1, 2020 to March 31, 2022, which was reduced to 1% on April 1, 2022 and was eliminated effective July 1, 2022.

The CARES Act also provides for certain federal income and other tax changes. We received a cash benefit of approximately $39.3 million for 2020 relating to the delay of payment of the employer portion of Social Security payroll taxes. We repaid half of the $39.3 million of payroll tax deferrals during the third quarter of 2021 and repaid the remaining portion in the third quarter of 2022 to eliminate the liability.

In addition to the financial and other relief that has been provided by the federal government through the CARES Act and other legislation passed by Congress, CMS and many state governments have also issued waivers and temporary suspensions of healthcare facility licensure, certification, and reimbursement requirements in order to provide hospitals, physicians, and other healthcare providers with increased flexibility to meet the challenges presented by the COVID-19 pandemic. For example, CMS and many state governments have temporarily eased regulatory requirements and burdens for delivering and being reimbursed for healthcare services provided remotely through telemedicine. CMS has also temporarily waived many provisions of the Stark law, including many of the provisions affecting our relationships with physicians. Many states have also suspended the enforcement of certain regulatory requirements to ensure that healthcare providers have sufficient capacity to treat COVID-19 patients. These regulatory changes are temporary, with most slated to expire at the end of the declared COVID-19 public health emergency.

We are continuing to evaluate the terms and conditions and financial impact of funds received under the CARES Act and other government relief programs.

### Results of Operations

The following table illustrates our consolidated results of operations for the respective periods shown (dollars in thousands):

|  | Three Months Ended September 30, 2022 Amount% |  | 2021 Amount% |  | Nine Months Ended September 30, 2022 Amount% |  | 2021 Amount% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $666,732 | 100.0% | $587,559 | 100.0% | $1,935,104 | 100.0% | $1,720,914 | 100.0% |
| Salaries, wages and benefits | 352,582 | 52.9% | 309,118 | 52.6% | 1,027,732 | 53.1% | 922,684 | 53.6% |
| Professional fees | 40,367 | 6.1% | 35,602 | 6.1% | 117,718 | 6.1% | 101,915 | 5.9% |
| Supplies | 25,570 | 3.8% | 23,743 | 4.0% | 74,291 | 3.8% | 67,698 | 3.9% |
| Rents and leases | 11,339 | 1.7% | 9,658 | 1.6% | 33,780 | 1.7% | 28,690 | 1.7% |
| Other operating expenses | 88,993 | 13.3% | 76,502 | 13.0% | 255,355 | 13.2% | 222,263 | 12.9% |
| Income from provider relief fund | (7,656) | -1.1% | — | 0.0% | (16,206) | -0.8% | — | 0.0% |
| Depreciation and amortization | 29,573 | 4.4% | 27,805 | 4.7% | 87,627 | 4.5% | 78,349 | 4.6% |
| Interest expense | 18,003 | 2.7% | 15,706 | 2.7% | 50,355 | 2.6% | 61,420 | 3.6% |
| Debt extinguishment costs | — | 0.0% | — | 0.0% | — | 0.0% | 24,650 | 1.4% |
| Loss on impairment | — | 0.0% | 1,079 | 0.2% | — | 0.0% | 24,293 | 1.4% |
| Transaction-related expenses | 10,859 | 1.6% | 3,035 | 0.5% | 18,381 | 0.9% | 9,320 | 0.5% |
| Total expenses | 569,630 | 85.4% | 502,248 | 85.4% | 1,649,033 | 85.1% | 1,541,282 | 89.5% |
| Income from continuing operations before income taxes | 97,102 | 14.6% | 85,311 | 14.6% | 286,071 | 14.9% | 179,632 | 10.5% |
| Provision for income taxes | 24,056 | 3.6% | 17,411 | 3.0% | 69,183 | 3.6% | 42,948 | 2.5% |
| Income from continuing operations | 73,046 | 11.0% | 67,900 | 11.6% | 216,888 | 11.3% | 136,684 | 8.0% |
| Loss from discontinued operations, net of taxes | — | 0.0% | — | 0.0% | — | 0.0% | (12,641) | -0.8% |
| Net income | 73,046 | 11.0% | 67,900 | 11.6% | 216,888 | 11.3% | 124,043 | 7.2% |
| Net income attributable to noncontrolling interests | (1,947) | -0.3% | (1,774) | -0.3% | (4,873) | -0.3% | (3,686) | -0.2% |
| Net income attributable to Acadia Healthcare Company, Inc. | $71,099 | 10.7% | $66,126 | 11.3% | $212,015 | 11.0% | $120,357 | 7.0% |

At September 30, 2022, we operated 242 behavioral healthcare facilities with approximately 10,800 beds in 39 states and Puerto Rico. For all periods presented, results of operations and cash flows of the U.K. operations are reported as discontinued operations in the accompanying financial statements.

We are encouraged by the favorable trends in our business and believe we are well positioned to capitalize on the expected growth in demand for behavioral health services. As with many other healthcare providers and other industries across the country, we are currently dealing with a tight labor market. However, we believe the diversity of our markets and service lines and our proactive focus helps us manage through this environment. We remain focused on ensuring that we have the level of staff to meet the demand in our markets.

The following table sets forth percent changes in same facility operating data for the three and nine months ended September 30, 2022 compared to the same period in 2021:

| U.S. Same Facility Results (a) | Three Months Ended | Nine Months Ended |
| --- | ---: | ---: |
| Revenue growth | 10.2% | 9.1% |
| Patient days growth | 3.1% | 2.0% |
| Admissions growth | 0.6% | -2.2% |
| Average length of stay change (b) | 2.5% | 4.3% |
| Revenue per patient day growth | 6.9% | 7.0% |
| Adjusted EBITDA margin change (c) | 150 bps | 190 bps |
| Adjusted EBITDA margin excluding income from provider relief fund (d) | 30 bps | 100 bps |

(a) Results for the periods presented include facilities we have operated more than one year and exclude certain closed services.

(b) Average length of stay is defined as patient days divided by admissions.

(c) Adjusted EBITDA is defined as income before provision for income taxes, equity-based compensation expense, debt extinguishment costs, loss on impairment, transaction-related expenses, interest expense and depreciation and amortization. Management uses Adjusted EBITDA as an analytical indicator to measure performance and to develop strategic objectives and operating plans. Adjusted EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Adjusted EBITDA should not be considered as a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies.

(d) For the three and nine months ended September 30, 2022, excludes income from provider relief fund of $7.7 million and $16.2 million, respectively.

### Three months ended September 30, 2022 compared to the three months ended September 30, 2021

*Revenue.* Revenue increased $79.2 million, or 13.5%, to $666.7 million for the three months ended September 30, 2022 from $587.6 million for the three months ended September 30, 2021. The increase includes revenue generated from our acquisition of CenterPointe on December 31, 2021. Same facility revenue increased $59.4 million, or 10.2%, for the three months ended September 30, 2022 compared to the three months ended September 30, 2021, resulting from an increase in same facility revenue per day of 6.9% and same facility growth in patient days of 3.1%. Consistent with same facility revenue growth in 2021, the growth in same facility patient days for the three months ended September 30, 2022 compared to the three months ended September 30, 2021 resulted from the addition of beds to our existing facilities and ongoing demand for our services.

*Salaries, wages and benefits.* Salaries, wages and benefits (“SWB”) expense was $352.6 million for the three months ended September 30, 2022 compared to $309.1 million for the three months ended September 30, 2021, an increase of $43.5 million. SWB expense included $7.2 million and $8.9 million of equity-based compensation expense for the three months ended September 30, 2022 and 2021, respectively. Excluding equity-based compensation expense, SWB expense was $345.4 million, or 51.8% of revenue, for the three months ended September 30, 2022, compared to $300.2 million, or 51.1% of revenue, for the three months ended September 30, 2021. The increase in SWB expense relates to SWB expense incurred by facilities acquired in the CenterPointe acquisition and incremental staff to support volume growth as well as wage inflation. Same facility SWB expense was $306.2 million for the three months ended September 30, 2022, or 47.8% of revenue, compared to $276.1 million for the three months ended September 30, 2021, or 47.5% of revenue.

*Professional fees.* Professional fees were $40.4 million for the three months ended September 30, 2022, or 6.1% of revenue, compared to $35.6 million for the three months ended September 30, 2021, or 6.1% of revenue. Same facility professional fees were $33.4 million for the three months ended September 30, 2022, or 5.2% of revenue, compared to $32.4 million for the three months ended September 30, 2021, or 5.6% of revenue.

*Supplies.* Supplies expense was $25.6 million for the three months ended September 30, 2022, or 3.8% of revenue, compared to $23.7 million for the three months ended September 30, 2021, or 4.0% of revenue. Same facility supplies expense was $24.1 million for the three months ended September 30, 2022, or 3.8% of revenue, compared to $23.3 million for the three months ended September 30, 2021, or 4.0% of revenue.

*Rents and leases.* Rents and leases were $11.3 million for the three months ended September 30, 2022, or 1.7% of revenue, compared to $9.7 million for the three months ended September 30, 2021, or 1.6% of revenue. Same facility rents and leases were $9.2 million for the three months ended September 30, 2022, or 1.4% of revenue, compared to $8.8 million for the three months ended September 30, 2021, or 1.5% of revenue.

*Other operating expenses.* Other operating expenses consisted primarily of purchased services, utilities, insurance, travel and repairs and maintenance expenses. Other operating expenses were $89.0 million for the three months ended September 30, 2022, or 13.3% of revenue, compared to $76.5 million for the three months ended September 30, 2021, or 13.0% of revenue. Same facility other operating expenses were $79.5 million for the three months ended September 30, 2022, or 12.4% of revenue, compared to $71.9 million for the three months ended September 30, 2021, or 12.4% of revenue.

*Income from provider relief fund.* For the three months ended September 30, 2022, we recorded $7.7 million in income from provider relief fund related to PHSSE funds received in 2022.

*Depreciation and amortization.* Depreciation and amortization expense was $29.6 million for the three months ended September 30, 2022, or 4.4% of revenue, compared to $27.8 million for the three months ended September 30, 2021, or 4.7% of revenue.

*Interest expense.* Interest expense was $18.0 million for the three months ended September 30, 2022 compared to $15.7 million for the three months ended September 30, 2021.

*Loss on impairment.* During the three months ended September 30, 2021, we recorded a $1.1 million non-cash property impairment charge for one facility in Louisiana resulting from hurricane damage.

*Transaction-related expenses.* Transaction-related expenses were $10.9 million for the three months ended September 30, 2022, compared to $3.0 million for the three months ended September 30, 2021. Transaction-related expenses represent legal, accounting, termination, restructuring, management transition, acquisition and other similar costs incurred in the respective period, as summarized below (in thousands).

|  | Three Months Ended September 30, 2022 | 2021 |
| --- | ---: | ---: |
| Management transition costs | $5,626 | $— |
| Termination and restructuring costs | 3,213 | 660 |
| Legal, accounting and other acquisition-related costs | 2,020 | 2,375 |
|  | $10,859 | $3,035 |

*Provision for income taxes.* For the three months ended September 30, 2022, the provision for income taxes was $24.1 million, reflecting an effective tax rate of 24.8%, compared to $17.4 million, reflecting an effective tax rate of 20.4%, for the three months ended September 30, 2021. The increase in the effective tax rate for the three months ended September 30, 2022 was primarily attributable to impacts of employee equity compensation awards in relation to income before income taxes.

As we continue to monitor the implications of potential tax legislation in each of our jurisdictions, we may adjust our estimates and record additional amounts for tax assets and liabilities. Any adjustments to our tax assets and liabilities could materially impact our provision for income taxes and our effective tax rate in the periods in which they are made.

### Nine months ended September 30, 2022 compared to the nine months ended September 30, 2021

*Revenue.* Revenue increased $214.2 million, or 12.4%, to $1,935.1 million for the nine months ended September 30, 2022 from $1,720.9 million for the nine months ended September 30, 2021. The increase includes revenue generated from our acquisition of CenterPointe on December 31, 2021. Same facility revenue increased $155.3 million, or 9.1%, for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021, resulting from an increase in same facility revenue per day of 7.0% and same facility growth in patient days of 2.0%. Consistent with same facility revenue growth in 2021, the growth in same facility patient days for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 resulted from the addition of beds to our existing facilities and ongoing demand for our services.

*Salaries, wages and benefits.* SWB expense was $1,027.7 million for the nine months ended September 30, 2022 compared to $922.7 million for the nine months ended September 30, 2021, an increase of $105.0 million. SWB expense included $21.7 million and $25.0 million of equity-based compensation expense for the nine months ended September 30, 2022 and 2021, respectively. Excluding equity-based compensation expense, SWB expense was $1,006.0 million, or 52.0% of revenue, for the nine months ended September 30, 2022, compared to $897.7 million, or 52.2% of revenue, for the nine months ended September 30, 2021. The increase in SWB expense relates to SWB expense incurred by facilities acquired in the CenterPointe acquisition and incremental staff to support volume growth as well as wage inflation. Same facility SWB expense was $892.5 million for the nine months ended September 30, 2022, or 48.0% of revenue, compared to $827.7 million for the nine months ended September 30, 2021, or 48.6% of revenue.

*Professional fees.* Professional fees were $117.7 million for the nine months ended September 30, 2022, or 6.1% of revenue, compared to $101.9 million for the nine months ended September 30, 2021, or 5.9% of revenue. Same facility professional fees were $99.3 million for the nine months ended September 30, 2022, or 5.3% of revenue, compared to $92.1 million, for the nine months ended September 30, 2021, or 5.4% of revenue.

*Supplies.* Supplies expense was $74.3 million for the nine months ended September 30, 2022, or 3.8% of revenue, compared to $67.7 million for the nine months ended September 30, 2021, or 3.9% of revenue. Same facility supplies expense was $70.3 million for the nine months ended September 30, 2022, or 3.8% of revenue, compared to $67.0 million for the nine months ended September 30, 2021, or 3.9% of revenue.

*Rents and leases.* Rents and leases were $33.8 million for the nine months ended September 30, 2022, or 1.7% of revenue, compared to $28.7 million for the nine months ended September 30, 2021, or 1.7% of revenue. Same facility rents and leases were $27.4 million for the nine months ended September 30, 2022, or 1.5% of revenue, compared to $26.0 million for the nine months ended September 30, 2021, or 1.5% of revenue.

*Other operating expenses.* Other operating expenses consisted primarily of purchased services, utilities, insurance, travel and repairs and maintenance expenses. Other operating expenses were $255.4 million for the nine months ended September 30, 2022, or 13.2% of revenue, compared to $222.3 million for the nine months ended September 30, 2021, or 12.9% of revenue. Same facility other operating expenses were $229.9 million for the nine months ended September 30, 2022, or 12.4% of revenue, compared to $214.1 million for the nine months ended September 30, 2021, or 12.6% of revenue.

*Income from provider relief fund.* For the nine months ended September 30, 2022, we recorded $16.2 million in income from provider relief fund related to PHSSE funds received in 2021 and 2022.

*Depreciation and amortization.* Depreciation and amortization expense was $87.6 million for the nine months ended September 30, 2022, or 4.5% of revenue, compared to $78.3 million for the nine months ended September 30, 2021, or 4.6% of revenue.

*Interest expense.* Interest expense was $50.4 million for the nine months ended September 30, 2022 compared to $61.4 million for the nine months ended September 30, 2021. The decrease in interest expense was primarily due to debt repayments in connection with the U.K. Sale.

*Debt extinguishment costs.* Debt extinguishment costs were $24.7 million for the nine months ended September 30, 2021 and represented $6.3 million of cash charges and $18.4 million of non-cash charges in connection with the redemption of the 5.625% Senior Notes and the 6.500% Senior Notes and the termination of the Prior Credit Facility.

*Loss on impairment.* Loss on impairment was $24.3 million for the nine months ended September 30, 2021. During the second quarter of 2021, we opened a 260-bed replacement facility in Pennsylvania and recorded a non-cash property impairment charge of $23.2 million for the existing facility. Additionally, during the third quarter of 2021, we recorded a $1.1 million non-cash property impairment charge for one facility in Louisiana resulting from hurricane damage.

*Transaction-related expenses.* Transaction-related expenses were $18.4 million for the nine months ended September 30, 2022, compared to $9.3 million for the nine months ended September 30, 2021. Transaction-related expenses represent legal, accounting, termination, restructuring, management transition, acquisition and other similar costs incurred in the respective period, as summarized below (in thousands).

|  | Nine Months Ended September 30, 2022 | 2021 |
| --- | ---: | ---: |
| Management transition costs | $7,826 | $— |
| Termination and restructuring costs | 5,859 | 3,853 |
| Legal, accounting and other acquisition-related costs | 4,696 | 5,467 |
|  | $18,381 | $9,320 |

*Provision for income taxes.* For the nine months ended September 30, 2022, the provision for income taxes was $69.2 million, reflecting an effective tax rate of 24.2%, compared to $42.9 million, reflecting an effective tax rate of 23.9%, for the nine months ended September 30, 2021. The increase in the effective tax rate for the three months ended September 30, 2022 was primarily attributable to impacts of employee equity compensation awards in relation to income before income taxes.

As we continue to monitor the implications of potential tax legislation in each of our jurisdictions, we may adjust our estimates and record additional amounts for tax assets and liabilities. Any adjustments to our tax assets and liabilities could materially impact our provision for income taxes and our effective tax rate in the periods in which they are made.

### Revenue

Our revenue is primarily derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care and adolescent residential treatment. We receive payments from the following sources for services rendered in our facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by CMS; and (iv) individual patients and clients. We determine the transaction price based on established billing rates reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and implicit price concessions. Contractual adjustments and discounts are based on contractual agreements, discount policies and historical experience. Implicit price concessions are based on historical collection experience.

The following table presents revenue by payor type and as a percentage of revenue for the three and nine months ended September 30, 2022 and 2021 (dollars in thousands):

|  | Three Months Ended September 30, 2022 Amount% |  | 2021 Amount% |  | Nine Months Ended September 30, 2022 Amount% |  | 2021 Amount% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Commercial | $193,186 | 29.0% | $170,427 | 29.0% | $589,553 | 30.5% | $511,975 | 29.8% |
| Medicare | 100,869 | 15.1% | 97,529 | 16.6% | 292,242 | 15.1% | 274,208 | 15.9% |
| Medicaid | 342,475 | 51.4% | 288,092 | 49.0% | 968,666 | 50.1% | 845,128 | 49.1% |
| Self-Pay | 20,046 | 3.0% | 25,998 | 4.4% | 58,532 | 3.0% | 71,875 | 4.2% |
| Other | 10,156 | 1.5% | 5,513 | 1.0% | 26,111 | 1.3% | 17,728 | 1.0% |
| Revenue | $666,732 | 100.0% | $587,559 | 100.0% | $1,935,104 | 100.0% | $1,720,914 | 100.0% |

The following tables present a summary of our aging of accounts receivable at September 30, 2022 and December 31, 2021:

### September 30, 2022

|  | Current | 30-90 | 90-150 | \>150 | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| Commercial | 19.5% | 4.7% | 3.0% | 8.2% | 35.4% |
| Medicare | 10.9% | 1.5% | 0.6% | 1.4% | 14.4% |
| Medicaid | 33.2% | 3.6% | 1.6% | 4.6% | 43.0% |
| Self-Pay | 1.4% | 1.4% | 1.3% | 2.6% | 6.7% |
| Other | 0.2% | 0.2% | 0.0% | 0.1% | 0.5% |
| Total | 65.2% | 11.4% | 6.5% | 16.9% | 100.0% |

30

### December 31, 2021

|  | Current | 30-90 | 90-150 | \>150 | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| Commercial | 20.1% | 6.2% | 2.6% | 8.2% | 37.1% |
| Medicare | 11.3% | 1.7% | 0.5% | 2.0% | 15.5% |
| Medicaid | 28.6% | 3.5% | 2.0% | 5.6% | 39.7% |
| Self-Pay | 1.3% | 1.4% | 1.4% | 3.0% | 7.1% |
| Other | 0.1% | 0.1% | 0.2% | 0.2% | 0.6% |
| Total | 61.4% | 12.9% | 6.7% | 19.0% | 100.0% |

### Liquidity and Capital Resources

Cash provided by continuing operating activities for the nine months ended September 30, 2022 was $267.0 million compared to $276.4 million for the nine months ended September 30, 2021. Operating cash flows included net government relief funds paid of approximately $32.6 million for the nine months ended September 30, 2022 compared to net government relief funds paid of approximately $12.1 million for the nine months ended September 30, 2021. Operating cash flows were impacted by an increase in earnings, a reduction in cash paid for interest and an increase in tax payments during the nine months ended September 30, 2022. Days sales outstanding were 44 days at September 30, 2022 compared to 42 days at December 31, 2021.

Cash used in investing activities for the nine months ended September 30, 2022 was $213.8 million compared to cash provided by investing activities of $1,243.1 million for the nine months ended September 30, 2021. Cash used in investing activities for the nine months ended September 30, 2022 primarily consisted of $208.8 million of cash paid for capital expenditures and $6.8 million of other, offset by $1.8 million of proceeds from sales of property and equipment. Cash paid for capital expenditures for the nine months ended September 30, 2022 consisted of $47.0 million of routine capital expenditures and $161.8 million of expansion capital expenditures. We define expansion capital expenditures as those that increase the capacity of our facilities or otherwise enhance revenue. Routine or maintenance capital expenditures were approximately 2.4% of revenue for the nine months ended September 30, 2022. Cash provided by investing activities for the nine months ended September 30, 2021 primarily consisted of $1,511.0 million of proceeds from the U.K. Sale, $3.1 million of other and $1.8 million of proceeds from the sale of property and equipment, offset by $156.6 million of cash paid for capital expenditures, $84.8 million for settlement of foreign currency derivatives and $31.4 million of cash paid for the purchase of a finance lease. Cash paid for capital expenditures for the nine months ended September 30, 2021 consisted of $31.0 million of routine capital expenditures and $125.6 million of expansion capital expenditures.

Cash used in financing activities for the nine months ended September 30, 2022 was $93.6 million compared to $1,706.2 million for the nine months ended September 30, 2021. Cash used in financing activities for the nine months ended September 30, 2022 consisted of principal payments on revolving credit facility of $85.0 million, principal payments on long-term debt of $13.3 million, repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises of $7.5 million and distributions to noncontrolling partners in joint ventures of $1.0 million, offset by $13.2 million of contributions from noncontrolling partners in joint ventures. Cash used in financing activities for the nine months ended September 30, 2021 primarily consisted of repayment of long-term debt of $2,227.9 million, principal payments on revolving credit facility of $330.0 million, payment of debt issuance costs of $8.0 million, other of $6.9 million and principal payments on long-term debt of $5.3 million, offset by borrowings on revolving credit facility of $430.0 million, borrowings on long-term debt of $425.0 million, repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises of $16.1 million and $1.8 million of contributions from noncontrolling partners in joint ventures.

We had total available cash and cash equivalents of $93.4 million and $133.8 million at September 30, 2022 and December 31, 2021, respectively, of which approximately $20.5 million and $20.1 million was held by our foreign subsidiaries, respectively. Our strategic plan does not require the repatriation of foreign cash in order to fund our operations in the U.S.

We believe existing cash on hand, cash flows from operations, the availability under our revolving line of credit and cash from additional financing will be sufficient to meet our expected liquidity needs during the next 12 months.

### New Credit Facility

We entered into a New Credit Facility on March 17, 2021. The New Credit Facility provides for a $600.0 million Revolving Facility and a $425.0 million Term Loan Facility with each maturing on March 17, 2026 unless extended in accordance with the terms of the New Credit Facility. The Revolving Facility further provides for (i) up to $20.0 million to be utilized for the issuance of letters of credit and (ii) the availability of a swingline facility under which we may borrow up to $20.0 million.

As a part of the closing of the New Credit Facility on March 17, 2021, we (i) refinanced and terminated our Prior Credit Facility and (ii) financed the redemption of all of our outstanding 5.625% Senior Notes.

During the nine months ended September 30, 2022, we repaid $85.0 million of the balance outstanding on the Revolving Facility. We had $511.6 million of availability under the Revolving Facility and had standby letters of credit outstanding of $3.4 million related to security for the payment of claims required by our workers’ compensation insurance program at September 30, 2022.

The New Credit Facility requires quarterly term loan principal repayments for our Term Loan Facility of $5.3 million for December 31, 2022 to March 31, 2024, $8.0 million for June 30, 2024 to March 31, 2025, $10.6 million for June 30, 2025 to December 31, 2025, with the remaining principal balance of the Term Loan Facility due on the maturity date of March 17, 2026.

We have the ability to increase the amount of the Senior Facilities, which may take the form of increases to the Revolving Facility or the Term Loan Facility or the issuance of one or more Incremental Facilities, upon obtaining additional commitments from new or existing lenders and the satisfaction of customary conditions precedent for such Incremental Facilities. Such Incremental Facilities may not exceed the sum of (i) the greater of $480.0 million and an amount equal to 100% of our Consolidated EBITDA (as defined in the New Credit Facility) and its Restricted Subsidiaries (as defined in the New Credit Facility) (as determined for the four fiscal quarter period most recently ended for which financial statements are available), and (ii) additional amounts so long as, after giving effect thereto, the Consolidated Senior Secured Net Leverage Ratio (as defined in the New Credit Facility) does not exceed 3.5 to 1.0.

Subject to certain exceptions, substantially all of our existing and subsequently acquired or organized direct or indirect wholly-owned U.S. subsidiaries are required to guarantee the repayment of obligations under the New Credit Facility. Borrowings under the Senior Facilities bear interest at a floating rate, which will initially be, at our option, either (i) adjusted LIBOR plus 1.375% or (ii) an alternative base rate plus 0.375% (in each case, subject to adjustment based on our consolidated total net leverage ratio). An unused fee initially set at 0.20% per annum (subject to adjustment based on our consolidated total net leverage ratio) is payable quarterly in arrears based on the actual daily undrawn portion of the commitments in respect of the Revolving Facility.

The interest rates and the unused line fee on unused commitments related to the Senior Facilities are based upon the following pricing tiers:

| Pricing Tier | Consolidated Total Net Leverage Ratio | Eurodollar Rate Loans and Letter of Credit Fees | Base Rate and Swing Line Loans | Commitment Fee |
| ---: | --- | ---: | ---: | ---: |
| 1 | ≥ 4.50:1.0 | 2.250% | 1.250% | 0.350% |
| 2 | \<4.50:1.0 but ≥ 3.75:1.0 | 2.000% | 1.000% | 0.300% |
| 3 | \<3.75:1.0 but ≥ 3.00:1.0 | 1.750% | 0.750% | 0.250% |
| 4 | \<3.00:1.0 but ≥ 2.25:1.0 | 1.500% | 0.500% | 0.200% |
| 5 | \<2.25:1.0 | 1.375% | 0.375% | 0.200% |

The New Credit Facility contains customary representations and affirmative and negative covenants, including limitations on the Company’s and its subsidiaries’ ability to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions, pay junior indebtedness and enter into affiliate transactions, in each case, subject to customary exceptions. In addition, the New Credit Facility contains financial covenants requiring us on a consolidated basis to maintain, as of the last day of any consecutive four fiscal quarter period, a consolidated total net leverage ratio of not more than 5.0 to 1.0 and an interest coverage ratio of at least 3.0 to 1.0. The New Credit Facility also includes events of default customary for facilities of this type and upon the occurrence of such events of default, among other things, all outstanding loans under the Senior Facilities may be accelerated and/or the lenders’ commitments terminated. At September 30, 2022, we were in compliance with such covenants.

### Prior Credit Facility

We entered into the Senior Secured Credit Facility on April 1, 2011. On December 31, 2012, we entered into the Prior Credit Facility which amended and restated the Senior Secured Credit Facility. We amended the Prior Credit Facility from time to time as described in our prior filings with the SEC.

On January 5, 2021, we made a voluntary payment of $105.0 million on the Tranche B-4 Facility. On January 19, 2021, we used a portion of the net proceeds from the U.K. Sale to repay the outstanding balances of $311.7 million of our TLA Facility and $767.9 million of our Tranche B-4 Facility of the Prior Credit Facility. In connection with the termination of the Prior Credit Facility, we recorded a debt extinguishment charge of $10.9 million, including the write-off of discount and deferred financing costs, which was recorded in debt extinguishment costs in the condensed consolidated statement of operations for the nine months ended September 30, 2021.

### Senior Notes

### 5.500% Senior Notes due 2028

On June 24, 2020, we issued $450.0 million of 5.500% Senior Notes due 2028. The 5.500% Senior Notes mature on July 1, 2028 and bear interest at a rate of 5.500% per annum, payable semi-annually in arrears on January 1 and July 1 of each year, commencing on January 1, 2021.

### 5.000% Senior Notes due 2029

On October 14, 2020, we issued $475.0 million of 5.000% Senior Notes. The 5.000% Senior Notes mature on April 15, 2029 and bear interest at a rate of 5.000% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, commencing on April 15, 2021.

The indentures governing the Senior Notes contain covenants that, among other things, limit our ability and the ability of our restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of our assets; and (vii) create liens on assets.

The Senior Notes issued by us are guaranteed by each of our subsidiaries that guaranteed our obligations under the New Credit Facility. The guarantees are full and unconditional and joint and several.

We may redeem the Senior Notes at our option, in whole or part, at the dates and amounts set forth in the indentures.

### 5.625% Senior Notes due 2023

On February 11, 2015, we issued $375.0 million of 5.625% Senior Notes due 2023. On September 21, 2015, we issued $275.0 million of additional 5.625% Senior Notes. The additional notes formed a single class of debt securities with the 5.625% Senior Notes issued in February 2015. Giving effect to this issuance, we had outstanding an aggregate of $650.0 million of 5.625% Senior Notes. The 5.625% Senior Notes were to mature on February 15, 2023 and bear interest at a rate of 5.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year. On March 17, 2021, we redeemed the 5.625% Senior Notes.

### 6.500% Senior Notes due 2024

On February 16, 2016, we issued $390.0 million of 6.500% Senior Notes due 2024. The 6.500% Senior Notes were to mature on March 1, 2024 and bear interest at a rate of 6.500% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016. On March 1, 2021, we redeemed the 6.500% Senior Notes.

### Redemption of 5.625% Senior Notes and 6.500% Senior Notes

On January 29, 2021, we issued conditional notices of full redemption providing for the redemption in full of $650 million of 5.625% Senior Notes and $390 million of 6.500% Senior Notes to the holders of such notes.

On March 1, 2021, we satisfied and discharged the indentures governing the 6.500% Senior Notes. In connection with the redemption of the 6.500% Senior Notes, we recorded debt extinguishment costs of $10.5 million, including $6.3 million cash paid for breakage costs and the write-off of deferred financing costs of $4.2 million in the condensed consolidated statement of operations for the nine months ended September 30, 2021.

On March 17, 2021, we satisfied and discharged the indentures governing the 5.625% Senior Notes. In connection with the redemption of the 5.625% Senior Notes, we recorded debt extinguishment costs of $3.3 million, including the write-off of deferred financing and premiums costs in the condensed consolidated statement of operations for the nine months ended September 30, 2021.

### Contractual Obligations

The following table presents a summary of contractual obligations at September 30, 2022 (in thousands):

|  | Payments Due by Period Less Than 1 Year | 1-3 Years | 3-5 Years | More Than 5 Years | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| Long-term debt (a) | $89,233 | $196,634 | $505,919 | $985,125 | $1,776,911 |
| Operating lease liabilities (b) | 32,081 | 53,989 | 32,847 | 64,032 | 182,949 |
| Finance lease liabilities | 990 | 2,071 | 2,178 | 22,094 | 27,333 |
| Total obligations and commitments | $122,304 | $252,694 | $540,944 | $1,071,251 | $1,987,193 |

(a) Amounts include required principal and interest payments. The projected interest payments reflect the interest rates in place on our variable-rate debt at September 30, 2022.

(b) Amounts exclude variable components of lease payments.

### Critical Accounting Policies

Our goodwill and other indefinite-lived intangible assets, which consist of licenses and accreditations, trade names and certificates of need intangible assets that are not amortized, are evaluated for impairment annually during the fourth quarter or more frequently if events indicate the carrying value of a reporting unit may not be recoverable.

Subsequent to the U.K. Sale, as of our impairment test on October 1, 2021, we had one reporting unit, behavioral health services. The fair value of our behavioral health services reporting unit substantially exceeded its carrying value, and therefore no impairment was recorded.

There have been no material changes in our critical accounting policies at September 30, 2022 from those described in our Annual Report on Form 10-K for the year ended December 31, 2021.

## Market risk

As filed, 472 characters.

### Interest Rate Risk

Our interest expense is sensitive to changes in market interest rates. Our long-term debt outstanding at September 30, 2022 was composed of $913.9 million of fixed-rate debt and $486.6 million of variable-rate debt with interest based on LIBOR plus an applicable margin. Based on our borrowing level at September 30, 2022, a hypothetical 1% increase in interest rates would decrease our pretax income on an annual basis by approximately $4.9 million.

## Controls and procedures

As filed, 1,261 characters.

### Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, our management conducted an evaluation, with the participation of our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.

### Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the three months ended September 30, 2022 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

## Risk factors

As filed, 615 characters.

In addition to the other information set forth in this report, an investor should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The risks described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, are not the only risks facing the Company. Additional risks and uncertainties not currently known to management or that management currently deems immaterial also may materially, adversely affect the Company’s business, financial condition, operating results or cash flows.

Filed Nov 2, 2022.
Source: SEC EDGAR, the filing index for accession 0001564590-22-036269. Last ingested by Listed: Nov 4, 2026, 17:50 ET. No prices; not investment advice.
